Jump Financial LLC Purchases Shares of 50,473 Xencor, Inc. $XNCR

Key Points

• Jump Financial LLC invested approximately $537,000 in Xencor, Inc. by acquiring 50,473 shares during the first quarter, which represents around 0.07% ownership of the company.
• Xencor reported a quarterly revenue of $43.61 million, significantly exceeding analyst estimates of $22.59 million, and achieved a smaller loss of ($0.41) earnings per share, beating expectations of a greater loss.
• Several large investors, including RTW Investments LP and Nuveen Asset Management LLC, have increased their stakes in Xencor, indicating growing institutional interest in the biopharmaceutical firm.

Jump Financial LLC bought a new position in shares of Xencor, Inc. (NASDAQ:XNCR - Free Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 50,473 shares of the biopharmaceutical company's stock, valued at approximately $537,000. Jump Financial LLC owned 0.07% of Xencor as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in XNCR. Dimensional Fund Advisors LP grew its holdings in shares of Xencor by 7.3% during the 4th quarter. Dimensional Fund Advisors LP now owns 1,501,532 shares of the biopharmaceutical company's stock worth $34,509,000 after acquiring an additional 102,297 shares during the period. Tower Research Capital LLC TRC lifted its holdings in shares of Xencor by 132.5% during the 4th quarter. Tower Research Capital LLC TRC now owns 7,865 shares of the biopharmaceutical company's stock valued at $181,000 after buying an additional 4,482 shares during the period. Aquatic Capital Management LLC bought a new position in shares of Xencor during the 4th quarter valued at $235,000. Northern Trust Corp lifted its holdings in shares of Xencor by 19.3% during the 4th quarter. Northern Trust Corp now owns 747,152 shares of the biopharmaceutical company's stock valued at $17,170,000 after buying an additional 120,655 shares during the period. Finally, Comerica Bank increased its stake in shares of Xencor by 12.1% in the 4th quarter. Comerica Bank now owns 20,527 shares of the biopharmaceutical company's stock worth $472,000 after purchasing an additional 2,219 shares in the last quarter.

Insider Activity

In other news, Director Richard J. Ranieri sold 2,993 shares of the business's stock in a transaction on Monday, June 16th. The shares were sold at an average price of $9.22, for a total transaction of $27,595.46. Following the sale, the director directly owned 19,183 shares of the company's stock, valued at $176,867.26. The trade was a 13.50% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Ellen Feigal sold 2,993 shares of the company's stock in a transaction on Monday, June 16th. The shares were sold at an average price of $9.22, for a total transaction of $27,595.46. Following the completion of the sale, the director directly owned 19,183 shares in the company, valued at approximately $176,867.26. The trade was a 13.50% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 11,194 shares of company stock valued at $103,209 over the last ninety days. 4.76% of the stock is currently owned by insiders.

Xencor Price Performance

NASDAQ XNCR traded up $0.31 on Friday, hitting $8.68. The stock had a trading volume of 157,779 shares, compared to its average volume of 760,386. The business's fifty day moving average price is $8.28 and its 200 day moving average price is $9.69. Xencor, Inc. has a 52-week low of $6.92 and a 52-week high of $27.24. The stock has a market cap of $618.84 million, a price-to-earnings ratio of -3.62 and a beta of 0.82.

Xencor (NASDAQ:XNCR - Get Free Report) last released its quarterly earnings results on Wednesday, August 6th. The biopharmaceutical company reported ($0.41) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.78) by $0.37. Xencor had a negative net margin of 121.52% and a negative return on equity of 25.75%. The business had revenue of $43.61 million for the quarter, compared to analyst estimates of $22.59 million. During the same period in the previous year, the company earned ($1.07) earnings per share. The business's revenue for the quarter was up 82.4% on a year-over-year basis. As a group, sell-side analysts anticipate that Xencor, Inc. will post -3.68 EPS for the current year.

Analyst Ratings Changes

XNCR has been the subject of several analyst reports. Wedbush restated an "outperform" rating and issued a $26.00 price objective on shares of Xencor in a research note on Tuesday. Royal Bank Of Canada dropped their price objective on shares of Xencor from $32.00 to $15.00 and set an "outperform" rating for the company in a report on Thursday, August 21st. Bank of America downgraded shares of Xencor from a "buy" rating to a "neutral" rating and lowered their price target for the company from $23.00 to $12.00 in a report on Wednesday. Barclays lowered their price target on shares of Xencor from $22.00 to $6.00 and set an "underweight" rating for the company in a report on Thursday, May 8th. Finally, Wells Fargo & Company reduced their price objective on shares of Xencor from $33.00 to $27.00 and set an "overweight" rating on the stock in a research report on Thursday, August 7th. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Xencor has an average rating of "Moderate Buy" and an average target price of $22.25.

Xencor Profile

Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma.